Centessa Pharmaceuticals (CNTA) Non Operating Income (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Non Operating Income of -$1.0 million for Q1 2026, down 199.9% year-over-year from $1.0 million in Q1 2025, and down 1095.15% on a QoQ basis from $103000.0 in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 7 years of Non Operating Income data on file, last reported at -$1.0 million in Q1 2026.
- Quarterly Non Operating Income fell 199.9% year-over-year to -$1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $860000.0 (down 1.83% YoY) and the FY2025 annual result came in at $2.9 million, up 272.55% from the prior year.
- Non Operating Income eased to -$1.0 million in Q1 2026 per CNTA's latest filing, from $103000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $5.4 million in Q2 2022 and bottomed at -$4.0 million in Q4 2024.
- The 5-year median for Non Operating Income is -$878000.0 (2023), against an average of -$169823.5.
- The widest annual swing landed in 2022, when Non Operating Income surged 2905.76%; it then slumped 1154.29% in 2023.
- Tracing CNTA's Non Operating Income over 5 years: stood at -$70000.0 in 2022, then tumbled by 1154.29% to -$878000.0 in 2023, then tumbled by 351.94% to -$4.0 million in 2024, then surged by 102.6% to $103000.0 in 2025, then plunged by 1095.15% to -$1.0 million in 2026.
- Per Business Quant, the three latest CNTA Non Operating Income figures stand at -$1.0 million (Q1 2026), $103000.0 (Q4 2025), and -$1.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | -1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.03 Mn |
| Dec 31, 2025 | 103,000.00 |
| Sep 30, 2025 | -1.81 Mn |
| Jun 30, 2025 | 3.59 Mn |
| Mar 31, 2025 | 1.03 Mn |
| Dec 31, 2024 | -3.97 Mn |
| Sep 30, 2024 | 3.66 Mn |
| Jun 30, 2024 | 154,000.00 |
| Mar 31, 2024 | -1.54 Mn |
| Dec 31, 2023 | -878,000.00 |
| Sep 30, 2023 | -1.68 Mn |
| Jun 30, 2023 | -1.53 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Dec 31, 2022 | -70,000.00 |
| Sep 30, 2022 | -3.14 Mn |
| Jun 30, 2022 | 5.36 Mn |
| Mar 31, 2022 | 196,000.00 |
| Dec 31, 2021 | 235,000.00 |
| Sep 30, 2021 | -1.91 Mn |
| Jun 30, 2021 | -191,000.00 |
| Mar 31, 2021 | -2.51 Mn |
| Dec 31, 2020 | 160,000.00 |
| Sep 30, 2020 | 6,000.00 |
| Jun 30, 2020 | -10,000.00 |